FORTESTA Drug Patent Profile

When do Fortesta patents expire, and what generic alternatives are available?

Fortesta is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in FORTESTA is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fortesta

A generic version of FORTESTA was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for FORTESTA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	3
Patent Applications:	4,386
Drug Prices:	Drug price information for FORTESTA
What excipients (inactive ingredients) are in FORTESTA?	FORTESTA excipients list
DailyMed Link:	FORTESTA at DailyMed

See drug prices for FORTESTA

See drug sales revenues for FORTESTA

Recent Clinical Trials for FORTESTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	Phase 4
Endo Pharmaceuticals	Phase 4
Endo Pharmaceuticals	Phase 3

See all FORTESTA clinical trials

Paragraph IV (Patent) Challenges for FORTESTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTESTA	Gel	testosterone	10 mg/actuation	021463	1	2012-08-14

US Patents and Regulatory Information for FORTESTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	FORTESTA	testosterone	GEL, METERED;TRANSDERMAL	021463-001	Dec 29, 2010		DISCN	Yes	No

Expired US Patents for FORTESTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	FORTESTA	testosterone	GEL, METERED;TRANSDERMAL	021463-001	Dec 29, 2010
Endo Operations	FORTESTA	testosterone	GEL, METERED;TRANSDERMAL	021463-001	Dec 29, 2010

EU/EMA Drug Approvals for FORTESTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for FORTESTA

See the table below for patents covering FORTESTA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	418988
New Zealand	504423	Composition having enhanced penetration capabilities and irritation reducing systems
European Patent Office	1030668
World Intellectual Property Organization (WIPO)	9924041

Market Dynamics and Financial Trajectory for Fortesta

Last updated: February 16, 2026

Overview
Fortesta (testosterone topical gel, 2%) is a prescription testosterone gel marketed by Endo Pharmaceuticals. Approved by the FDA in 2014, it targets adult males with hypogonadism, a condition characterized by low testosterone levels. The drug's market presence is shaped by regulatory, clinical, and competitive factors.

Market Size and Growth
The global testosterone replacement therapy (TRT) market, including Fortesta, is projected to expand from approximately $2.7 billion in 2021 to over $4 billion by 2026, reflecting a compound annual growth rate (CAGR) of roughly 8.3% (source [1]). This growth is driven by increasing diagnosis of hypogonadism, aging male populations, and evolving treatment preferences.

Competitive Landscape
Fortesta competes within the topical TRT segment, which includes products like AndroGel, Testim, Axiron, and compounded formulations. Fortesta's share is limited; as of 2023, the TRT market leader, AndroGel, holds approximately 60% market share (source [2]). The segment is saturated with multiple formulations, impacting pricing power and market penetration.

Pricing and Revenue Trends
Fortesta had peak sales of approximately $50 million in 2017, driven by physician acceptance and reimbursement policies. Sales declined to about $20 million in 2021, due to manufacturer price reductions, competition, and label restrictions. As of 2022, revenue stabilized around $22 million, indicating limited growth potential without product differentiation or indications expansion.

Regulatory and Prescription Trends
The FDA issued warnings on testosterone therapy's cardiovascular risks, reducing prescribing rates, especially among older men. New guidelines favor conservative use, impacting market expansion. Stringent labeling and risk management plans restrict broad access.

Patent and Intellectual Property Status
Endo licensed Fortesta's formulation patents until around 2025. Patent expirations could open pathways for generic competition, exerting downward pressure on prices. No recent patent litigations or extensions have been announced.

Financial Outlook
Limited growth prospects for Fortesta are recent, constrained by market saturation. Future revenues depend on:

• Expansion into new indications such as gender dysphoria or pediatric hypogonadism.
• Differentiation through formulation improvements or combination therapies.
• Market share gains through physician education and reimbursement strategies.

Investment and R&D Considerations
Endo's R&D pipeline for TRT products remains modest; recent focus emphasizes alternative delivery systems and combination formulations. No significant pipeline updates for Fortesta itself have emerged since approval.

Key Challenges

• Market saturation with dominant competitors.
• Regulatory pressures reducing prescribing flexibility.
• Patent expirations decreasing exclusivity coverage.
• Safety concerns impacting physician and patient acceptance.

Opportunities

• Potential for indication expansion.
• Development of novel formulations with better safety profiles.
• Geographic expansion into emerging markets with increasing TRT adoption.

Conclusion
Fortesta remains a niche product within a highly competitive, mature market segment with limited near-term growth. Its financial trajectory relies on external factors such as patent lifecycle, competitive innovation, and regulatory environment. The product's sales are unlikely to grow substantially without strategic repositioning or pipeline development.

---

Key Takeaways

• The global TRT market is projected to grow annually at about 8.3%, but Fortesta's market share remains limited.
• Sales peaked around 2017, declined, then stabilized at roughly $22 million as of 2022.
• Patent expiration and competition threaten future revenues; pipeline development is minimal.
• Regulatory restrictions and safety concerns temper market expansion.
• Growth opportunities exist but require significant innovation or indication expansion.

---

FAQs

1. What is the primary market for Fortesta?
Adults with diagnosed hypogonadism, primarily in North America, where prescription patterns support testosterone therapy.

2. How does Fortesta compare to its competitors?
It has a smaller market share and limited differentiation from products like AndroGel and Testim, which dominate the topical TRT market.

3. What are the key challenges facing Fortesta’s growth?
Patent expirations, intense competition, regulatory restrictions, safety concerns, and market saturation.

4. Are there opportunities for Fortesta to expand its use?
Potentially through indication expansion into gender dysphoria or pediatric hypogonadism, but regulatory approval is uncertain.

5. How will patent expiry affect Fortesta?
Patents are set to expire around 2025, paving the way for generic entrants likely to reduce prices and sales.

---

Citations
[1] MarketsandMarkets, "Testosterone Replacement Therapy Market," 2022.
[2] IQVIA, Prescription Data, 2023.